Oulu, Finland – 16th February 2021
Paras Biopharmaceuticals Finland Oy (Paras Biopharma) is a Finland-based microbial biologics company which focuses on the development of technologies for biosimilars and biologics in an efficient manner. The overall objective of Paras Biopharma is to enable economical production and future availability of affordable medicines for unmet medical needs.
A recent review of Paras Biopharma outreach outlines strong interest in the company’s activities on global basis. The parasbiopharma.com website was viewed in 90+ countries globally. This strong interest in the company’s activities came from both USA/Europe (75%) and emerging / developing world countries (25%).
Paras Biopharma’s outreach efforts team is active on social media platforms with direct reach out to professionals working in similar fields. The company efforts are encouraging specially as affordable and better priced alternatives of expensive medicines/medicine production technologies are highly in demand and needed by millions of those patients and care groups who cannot afford expensive medicines.
“Biologics are a special class of medicines that are highly effective in meeting unmet medical needs but come with huge price tags. To address the high-cost issues, countries are heavily emphasizing on biosimilars (or follow-on biologics). At Paras Biopharmaceuticals, we have developed a unique portfolio of microbial biologics technologies for the production of biosimilars and complex biologics which increase the number of medication options and potentially lower costs” says Dr Mark Jackson, Administration Lead.
Paras Biopharma is committed to the development of innovative and high-quality biosimilars production technologies. The company has developed robust biosimilars technologies to cater the following: Osteoporosis, Rheumatoid Arthritis, Metabolic Diseases, Oncology
“Paras Biopharma anticipates that the companies from developed countries (in addition to those from emerging markets) are interested in our technologies capable of exploring production of difficult complex proteins. We are motivated to continue striving further and contributing to the goals of making healthcare affordable and meeting unmet medical needs” says Dr Ashesh Kumar, CEO of Paras Biopharmaceuticals.
Please contact info@parasbiopharma.com or visit our website www.parasbiopharma.com for further information.
Paras Biopharmaceutical Finland Oy joins PSL Alliance and its global membership to promote worldwide reach out for Paras' Bioprocess Enzymes
Oulu, Finland – 8th September 2020
Paras Biopharmaceuticals Finland Oy (Paras Biopharma) is pleased to announce that it is now a member of the Pivotal Scientific Limited (PSL) Alliance, a network of companies operating within the biotechnology market. As part of the Company’s portfolio of microbial products, technologies and bioprocess enzymes, Paras Biopharma looks forward to reaching out to distributors and subsequently to the end users for its recombinant bioprocess enzymes.
PSL Alliance provides a platform for manufacturers, suppliers, and distributors to communicate with the aim to forge successful working relationships and worldwide reach out. Paras Biopharma believes that its association with PSL will enable Paras Biopharma to reach out to a larger customer base and will help researchers and companies in their biopharmaceutical development needs.
Together with its existing portfolio of recombinant enzymes that include “RapidTEV® (recombinant TEV protease) and RapidEK® (recombinant Enterokinase), the Paras Biopharma team has successfully developed a new addition, RapidZymo® (recombinant Zymolyase).
“The development of RapidZymo® complements the Company’s existing portfolio of recombinant enzymes and proteases that are widely used for valuable biologics within research and development, including the cleavage of fusion proteins and removal of tags from recombinant proteins” said Dr Jordan Verrollot, Technical Associate, Paras Biopharmaceuticals.
“These enzymes are produced by Paras’ proprietary technology platform and have been engineered for enhanced activity and greater stability. The Company is proud of the efforts its Associates have made in developing these recombinant enzymes” said Dr Mark Jackson, Administration Lead, Paras Biopharmaceuticals.
“PSL appreciates and is pleased that Paras Biopharma has become a PSL Alliance member and it looks forward to working with the team at Paras Biopharma” said Richard Atkins, Commercial Director at Pivotal Scientific, UK.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharma is a Finnish biopharmaceuticals company that started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharma’s team has strong experience in developing biologics in the most efficient manner.
The Company’s primary objective is to strive to create solutions through manufacturing innovations in the bioprocessing & bioproduction space for difficult-to-produce Biologics and Biosimilars.
Company main activities & offerings are in 3 major areas:
1. Contract development & microbial biologics manufacturing (CDMO)
2. Development of technologies for the production of biosimilars & complex biologics
3. Recombinant Bioprocess Enzymes
Paras Biopharma has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharma proprietary technology platform consists of Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant® Technologies. http://www.parasbiopharma.com/enzymes.php
About Pivotal Scientific Limited (PSL) Alliance
Pivotal Scientific Limited is a unique biotechnology consultancy founded in 2008 by Tim Bernard, in response to a gap in the biotechnology market for a company that offered advice and support for small to medium-sized businesses operating within the research reagent sector. PSL’s main objective is to assist companies in growing their brand and sales in this highly competitive market by supporting them at all stages of the business life cycle pivotalscientific.com/our-consultancy-services/the-psl- alliance/
For more information on Paras Biopharma’s enzymes and the company, kindly reach out to us at BD@parasbiopharma.com. Please also visit our website www.parasbiopharma.com.
For other enquiries, please contact:
Dr Mark Jackson – email: mark.jackson@parasbiopharma.com
Dr Jordan Verrollot – email: jordan.verrollot@parasbiopharma.com
All the enzymes mentioned are for research & development purpose only and not for use in humans.
Paras Biopharmaceuticals Successfully Develops Cytofold StructQuant® Technology for Cytoplasmic Disulphide Formation, (for Active Folding) for Complex Therapeutic Proteins
Oulu, Finland – 10th September 2019
Paras Biopharmaceuticals Finland Oy is pleased to announce that its proprietary technology, Cytofold StructQuant®, is established for the high-level expression of homogeneously folded disulfide bond containing proteins in the cytoplasm of E. Coli. The technology offers all cost benefits of expression in E. Coli rather than in eukaryotic systems, while at the same time retaining the high yields obtained in cytoplasmic expression. The biologics produced are of the highest quality and have maximal biological activity.
In a nutshell, the advantages that this Cytofold® Technology allows:
These developments highlight the variance from previous systems – this technology works in any E.coli strain and does not require the disruption of the reducing pathways naturally present. The system also works in all media and does not require any supplementation of the media, therefore allowing a further reduction in costs.
"The system has been successful for the production in high yields. The successful development of Cytofold StructQuant® technology further adds to our already existing portfolio of bioprocess technology knowledge." says Dr. Ashesh Kumar, CEO. "We will be able to serve our clients better and more effectively, with higher quality and lower costs." says Dr. Mark Jackson, Administrative Lead, Paras Biopharmaceuticals.
Paras Biopharmaceuticals has successfully used Cytofold® technology along with the company's other technology Biomultifold® to produce difficult to manufacture proteins and will offer these technologies to CDMO clients and utilise in Biosimilar and Biologics production.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals' team has strong experience in developing biologics in the most efficient manner.
Company main activities & offerings are in 3 major areas:
1. Contract development & microbial biologics manufacturing (CDMO).
2. Development & Licensing of Biosimilars.
3. Recombinant Bioprocess Enzymes – TEV protease and Recombinant Enterokinase.
Paras Biopharmaceuticals has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals has developed and is now offering clinical development and marketing collaboration for the following Biosimilars: Recombinant Teriparatide (Forteo® Biosimilar), Recombinant Anakinra (Kineret® Biosimilar), Analog Insulin Aspart®, Recombinant Rasburicase (Elitek® / Fasturtec® Biosimilar) and Recombinant Romiplostim (N-plate® Biosimilar). The company has achieved efficient and cost-effective production of high value biosimilars. Paras Biopharmaceuticals has developed a proprietary platform which includes Diabrid® Technology, Noblecleav® Technology and Biomultifold® Technology.
*Nplate® is a registered trademark of Amgen Inc.
For further details, visit the following website: www.parasbiopharma.com
Fermentation suite at Paras Biopharmaceuticals' Oulu site. (Photo: Paras Biopharmaceuticals Finland Oy).
For further information, please contact:
Paras Biopharmaceuticals Finland Oy
Media Relations & Information
Dr Mark Jackson Tel: +358 442709462 / Email: info@parasbiopharma.com
Reuters to make documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a leading expert.
Date: Tuesday 7th May 2019
Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected our Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions.
The documentary is part of their ‘Global Thought Leaders’ series that will feature some of the world’s leading innovators, discussing how their industries/markets are evolving through the use of their latest technologies.
Paras Biopharmaceuticals Finland Oy has developed innovative manufacturing technologies, namely Diabrid®, NobleCleav® & Biomultifold® technologies which enables the economical production of complex biologics & long therapeutic peptides. Based on its innovations, the company has developed an important biologics and biosimilar products pipeline including a Romiplostim Biosimilar (for ITP), an Osteoporosis drug & a IL1-RA for multiple diseases.
Using its unique production technologies, Paras Biopharmaceuticals Finland Oy also provides contract development & manufacturing services (CDMO) & bioprocess enzymes to help bring affordable healthcare solutions for new medicines.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company that started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals’ team has strong experience in developing biologics in the most efficient manner.
Company main activities & offerings are in 3 major areas:
1. Contract development & microbial biologics manufacturing (CDMO).
2. Development & Licensing of Biosimilars.
3. Recombinant Bioprocess Enzymes – TEV protease and Recombinant Enterokinase.
Paras Biopharmaceuticals has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals has developed and is now offering clinical development and marketing collaboration for the following Biosimilars: Recombinant Teriparatide, Recombinant Anakinra (Kineret® Biosimilar), Recombinant Rasburicase and Recombinant Romiplostim (N-plate® Biosimilar).
Kineret® and *Nplate® are registered trademarks of Amgen Inc.
For further details, visit the following website: www.parasbiopharma.com
For further information, please contact:
Paras Biopharmaceuticals Finland Oy
Media Relations & Information
Dr Mark Jackson Tel: +358 442709462 / Email: mark.jackson@parasbiopharma.com
Penny Härkönen Tel: +358442709462 / Email: penny.harkonen@parasbiopharma.com
Oulu, Finland February 1st, 2019: – PARAS BIOPHARMACEUTICALS FINLAND OY today announced the achievement of a major milestone – the successful development of biologically active Romiplostim (N-Plate® biosimilar) production technology.
Romiplostim has been produced with a proprietary and innovative continuous manufacturing process at the company’s Finnish-based facility in Oulu-Finland. Romiplostim is used for the treatment of thrombocytopenia (low platelet count) in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
ITP is a potentially serious blood disorder characterized by increased destruction and impaired production of platelets. It can lead to extensive bruising and bleeding. Thrombocytopenia is common in cancer patients, resulting from chemotherapy or radiation treatment, in addition to the underlying disease itself. ITP leads to several complications. Low platelet count increases spontaneous bleeding, complicates surgical operations and can affect chemotherapy and radiation therapy.
By manufacturing its first batches of the Romiplostim biosimilar, Paras Biopharmaceuticals is in a position to prepare to initiate next steps for the drug substance and formulation in 2019 within its Romiplostim biosimilar development program. “The development and implementation of this commercial-scale manufacturing process for Romiplostim is not only good news for the company but the wider healthcare environment.” said Dr Ashesh Kumar, CEO & Director: Biologics & Licensing.
“The company is evaluating production batches to assess comparability and looks forward to finalizing this work in the anticipation of supporting clinical trials towards commercialization. &" says Dr Mark Jackson Research & Admin Group, Paras Biopharmaceuticals.
Global occurrence of ITP is increasing, and a growing number of patients diagnosed/reported to be affected. Current costs of available medicines are very expensive primarily due to higher production costs and inefficient production processes. Current yearly treatment in USA can cost up to $55250 USD per year for each ITP patient. With Paras Biopharmaceuticals efficient production technologies, the company aims to provide affordable healthcare treatment options to patients suffering from ITP.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals’ team has strong experience in developing biologics in the most efficient manner.
Company main activities & offerings are in 3 major areas:
Paras Biopharmaceuticals has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals has developed and is now offering clinical development and marketing collaboration for the following Biosimilars: Recombinant Teriparatide (Forteo® Biosimilar), Recombinant Anakinra (Kineret® Biosimilar), Analog Insulin Aspart®, Recombinant Rasburicase (Elitek® / Fasturtec® Biosimilar) and Recombinant Romiplostim (N-plate® Biosimilar). The company has achieved efficient and cost-effective production of high value biosimilars. Paras Biopharmaceuticals has developed a proprietary platform which includes Diabrid® Technology, Noblecleav® Technology and Biomultifold® Technology.
*Nplate® is a registered trademark of Amgen Inc.
For further details, visit the following website: www.parasbiopharma.com
Fermentation suite at Paras Biopharmaceuticals’ Oulu site. (Photo: Paras Biopharmaceuticals Finland Oy).
For further information, please contact:
Paras Biopharmaceuticals Finland Oy
Media Relations & Information
Dr Mark Jackson Tel: +358 442709462 / Email: mark.jackson@parasbiopharma.com
Penny Härkönen Tel: +358442709462 / Email: penny.harkonen@parasbiopharma.com
Oulu, October 9, 2018 - In Oulu, the Finnish-based group PARAS BIOPHARMACEUTICALS FINLAND OY is currently enhancing its quality systems and production facilities for biopharmaceuticals - also known as biologics - with significant investments in new infrastructure and equipment. These facilities will offer a state of the art, automation production facility to customers with the latest automation in biologics production, with increased employment opportunities over the next 2-5 years.
“In recent years, we have been continuously expanding our research & development and contract manufacturing capacity for biopharmaceuticals in Oulu. More recently, the company has invested over €6.0 million in new equipment upgrades and product development, which has enhanced Paras Biopharmaceuticals’ ability to develop and manufacture recombinant products in microbial systems. The new, modern production equipment is further enhancing the site, making our company meet stringent needs of regulatory compliance.”, explained Dr. Ashesh Kumar, CEO & Director: Biologics and Licensing.
The new equipment includes, among other things, automation systems for process control, upgradation of a speciality designed lyophilization and protein purification systems including AxiChrom & BPG columns. Furthermore, analytical capabilities were expanded with LC-MS-MS, GC-MS, HPLCs and new microbiology laboratory systems and equipment for process optimization and product characterization and validations. An automation system (LIMS) was installed in the analytical laboratory on efforts towards GLP compliance.
As a result, Paras Biopharmaceuticals’ Oulu site is fully equipped to supply the fast-growing market for biologics. Future-oriented therapeutic agents now make up 25 percent of the global pharmaceuticals market. Dr. Mark Jackson said, “The improvements will help in creating better technologies, thereby resulting in more affordable healthcare”.
About Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals’ team has strong experience in developing biologics in a most efficient manner.
Company main activities & offerings are in 3 major areas:
The company’s facility is for the production of recombinant products in microbial strains. The production set up has a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2. Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals Finland Oy - www.parasbiopharma.com
Oulu, Finland
Dr. Mark Jackson - mark.jackson@parasbiopharma.com - +358 442 709 462
Paras Biopharmaceuticals is pleased to announce that it has been awarded the Quality Choice Prize 2016 by the European Society for Quality Research (ESQR, Switzerland) on December 12, 2016 in Berlin.
Based on their products and its continuous drive to push the limits of Quality with innovations, Paras Biopharmaceuticals has received the ESQR’s Quality Choice Prize 2016 for their hard work and achievements, in the presence of the international business community for its commitment to quality, excellence and continuous improvement.
On behalf of Paras Biopharmaceuticals, Dr Hans Söderlund, Director: Global Strategy Alliance, received the award during the ceremony held in Berlin. "This award is yet another testament to the good work and dedication of all employees of Paras Biopharmaceuticals”. “It is a continuation of the recognition of Paras Biopharmaceuticals’ operational efforts and performance”.
“Paras Biopharmaceuticals is making its best efforts for developing quality products and efficient technologies for the production of biosimilars in osteoporosis and diabetes" says Dr Ashesh Kumar, CEO & Director: Biologics at Paras Biopharmaceuticals.
The ESQR’s Quality Choice Prize, run by the European Society for Quality Research recognizes the companies, organizations, public administrations with ethics and initiatives that demonstrate exceptional success in quality management and that maximize the full potential of their services through quality-oriented practices. The award takes a comprehensive look at the initiatives and strategies that business leaders implement in their companies and organizations; it recognizes the efforts of exceptional and talented employers and employees and provides motivation for continuous progress.
About Paras Biopharmaceuticals Finland Oy
Based in Oulu, Finland, Paras Biopharmaceuticals is a privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. The company’s facilities in Finland are dedicated to the development, scale-up and production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), oncology and high-value recombinant enzymes. Paras Biopharmaceuticals has successfully developed its Diabrid Technology Platform (Diabrid® Technology, NobleCleav® Technology and Biomultifold® Microbial High Expression Technology) for the development of biosimilars in specifically designed expression systems.
About ESQR
The European Society for Quality Research (ESQR), based in Lausanne (Switzerland), handles strategic questions in quality management and promotes Quality Culture and continuous improvement in Quality through the annual Conventions, which serve as a global forum to perfect quality management techniques and provides an excellent networking opportunity for all participants. The awarded companies, public administrations and organizations, from a wide range of private and public sectors, which strive for excellence and have proven their capabilities through their accomplishments, will renew their commitment to excellence and get new ideas on quality management.
Paras Biopharmaceuticals Finland Oy - www.parasbiopharma.com
Oulu, Finland
Dr Mark Jackson - mark.jackson@parasbiopharma.com +358 442905993
Oulu, Finland 25th August 2016, - Oulu-based Paras Biopharmaceuticals Finland Oy has developed technology for the production of an osteoporosis drug (Recombinant Teriparatide) which will result into a very economical production of the medicine. International pharma companies are actively in discussions with Paras Biopharmaceuticals to further take regulatory work and bring the medicine to market.
Furthermore, Paras Biopharmaceuticals has secured necessary investment from a UK group (ASAP Growth Ltd) who have extensive entrepreneurial experience in pharmaceuticals. This multi-million-euro investment is a key enabler in bringing further development of the product and the potential expansion of activities in Oulu. This belief in Paras Biopharmaceuticals has been further cemented by several big pharma companies who has approached the company for in-depth discussions. These are ongoing.
“A large number of biologics are very exorbitantly priced in the market which automatically makes it too expensive for many patients. Even in today’s financial climate, developed countries are having to think carefully before buying these products. The good news is that over 85% - 90% of biologics patents will go off patent in the next 10 years” says Dr Hans Söderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals. “These medicines are required across the world in a vast number of markets due to an ageing world population. Demand for some biologics such as osteoporosis are expected to grow significantly”
With the imminent expiry of several key “Blockbuster” biologics patents this has created not-to-be missed opportunities for biosimilar development and a chance for new companies to establish themselves as suppliers. According to Frost & Sullivan (a leading US investment group) in 2015, the total global biosimilar market was expected to generate $ 4.12 billion in sales. By 2017, this figure is expected to increase to $12.5 billion as more products become susceptible to biosimilar competition.
Based in Oulu, Paras Biopharmaceuticals has been actively working on developing and producing a biosimilar for the expensive osteoporosis drug “Forteo” manufactured by Eli Lilly. The innovative new process will complement its existing robust portfolio of propriety technologies to improve the efficiency and reduce the productions cost of the daily injection for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture.
Dr Mark Jackson - mark.jackson@parasbiopharma.com +358 442905993
In collaboration with Novozymes (Denmark), Paras Biopharmaceuticals (Finland) has announced that the partnership will use the successful VELTIS® technology to develop an improved version of a leading osteoporosis treatment.
Paras Biopharmaceuticals has teamed up with Novozymes to generate a ‘once-a-week’ biobetter of Teriparatide, a leading treatment for a debilitating bone disease largely affecting women over the age of 50. Osteoporosis is a major public health threat for an estimated 200 million women worldwide by weakening bones and increasing the risk of sudden and unexpected fractures. One in three women and one in five men over the age of 50 will break a bone due to osteoporosis in their lifetime.
Paras Biopharmaceuticals has developed a highly efficient production technology platform for the biosimilar of Recombinant Teriparatide (Forteo Biosimilar). Extending the release of the base molecule (to once-a-week) by incorporating Novozymes’ VELTIS technology will offer new solutions. Already well-established in the fields of diabetes, hemophilia and neutropenia, the VELTIS platform is able to provide once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact.
“Collective strengths of Paras Biopharmaceuticals’ and Novozymes’ technical expertise will bring solutions and treatment options for further convenience of osteoporosis patients” says Dr Hans Söderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals Finland Oy. “Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ Diabrid NobleCleav technology will create a superior osteoporosis medicine” adds Dr Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals Finland Oy.
“This is further market validation of the Novozymes Biopharma’s VELTIS technology”, says Svend Licht, Director, Novozymes Biopharma. “The versatile capabilities of our solution are being continually demonstrated by our customers. We are happy to enable the development of this biobetter, this in addition to running numerous collaborations in life cycle management and new drug candidates”.
About Paras Biopharmaceuticals Finland Oy
Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. The company’s facilities in Finland are dedicated to the development, scale-up and production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology, in addition to high value recombinant enzymes such as Enterokinase (and other enzymes in pipeline). Paras Biopharmaceuticals has successfully developed its Diabrid Technology Platform (Diabrid® Technology, NobleCleav® Technolgy and Biomultifold® Microbial High Expression Technolgy) for the high level expression of biosimilars in specially designed genetically stable clones.
(http://www.parasbiopharma.com)
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, its aim is to improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, its bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.
About VELTIS
VELTIS is a clinically-proven technology based on engineered albumins delivered to allow the drug developer to optimize dose size and frequency to achieve stricter patient adherence (compliance) for improved therapeutic impact by targeting once weekly, once bi-weekly, or once monthly dosing.
VELTIS is delivered by Novozymes Biopharma and is provided with access to Novzymes extensive technical and regulatory support as well as to partner providers. The technology is well-established in the fields of diabetes, haemophilia and neutropenia by Novozymes’ customers.
Today, Novozymes Biopharma is working together with a number of pharma companies who are exploring the possibilities of VELTIS as a platform for half-life extension. These companies include CSL, EpiVaX while GlaxoSmithKline is using VELTIS in a marketed drug for treatment of diabetes.
Paras Biopharmaceuticals Finland Oy - www.parasbiopharma.com
Oulu, Finland
Dr Mark Jackson - mark.jackson@parasbiopharma.com
+358 442905993
Kiviharjunlenkki 10, 90220 OULU, Finland
Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum
Paras Biopharmaceuticals Finland Oy, an upcoming biopharmaceutical manufacturing company for biosimilars and therapeutic peptides, announced today that it has been selected to present at the Cavendish Global Health Impact Forum taking place 10th - 14th May in La Jolla, California, USA. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Cavendish Impact Forums are hosted by leading institutions around the world including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.
Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Paras Biopharmaceuticals’ technologies (Diabrid® Technology, NobleCleav® Technolgy and Biomultifold® Microbial High Expression Technolgy) and scientific insights for the development of affordable biologics allows them to make a major contribution in targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.
“We are honoured to be selected as the first Finnish company (and only the second company in the Nordic region) to present at this unique event. Recognition of our efforts for the effective production of recombinant therapeutics to provide affordable healthcare affecting populations around the world,” said Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals.
“In a time of widespread economic austerity and increased pressure on Governments’ health budgets, demand for access to affordable healthcare is greater than ever. We welcome the opportunity to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world,” said Dr Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals.
About Paras Biopharmaceuticals
(http://www.parasbiopharma.com)
Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Our facilities in Finland are dedicated to the development, scale-up and production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.
About Cavendish Global
Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavours within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California.
Paras Biopharmaceuticals Finland Oy - www.parasbiopharma.com
Oulu, Finland
Dr Mark Jackson - mark.jackson@parasbiopharma.com
+358 442905993
Kiviharjunlenkki 10, 90220 OULU, Finland
Oulu, Finland 11th December 2014
Paras Biopharmaceuticals Finland Oy, a Finnish company based in Oulu has been recognized by Frost & Sullivan with the “2014 European Biopharmaceuticals Technology Innovation Leadership Award” for biopharmaceutical technology development.
Paras Biopharmaceuticals has built a robust portfolio of proprietary technologies for the production of therapeutic biomedicines for osteoporosis and diabetes. The Finnish company has developed innovative solutions for the effective and economic production of recombinant therapeutics.
Each year, Frost & Sullivan presents the Award for Technology Innovation Leadership (Europe) to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the high R&D quality towards innovation, its relevance to the industry and the positive impact on brand perception.
Paras Biopharmaceuticals has successfully developed three proprietary manufacturing technologies: Diabrid® Technology, NobleCleav® Technology and Biomultifold® Microbial High Expression Technology for the development of several biopharma active pharmaceuticals ingredients (APIs), targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology.
Diabrid® Technology works as a critical enabler for achieving the correct target product, NobleCleav® Technology facilitates the high-level production of authentic biologics by combining specificity and activity of processing of recombinant therapeutic peptides and proteins, while the Biomultifold® Microbial High Expression Technology helps to achieve expression levels of multigrams of therapeutic proteins per litre of fermentation using E.coli.
“In a time of widespread economic austerity, demand for access to affordable healthcare is greater than ever” says Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals. “This award by Frost & Sullivan recognises Paras Biopharmaceuticals’ hard work and commitment in developing more economical and efficient technologies for the production of biosimilars and noble biologics.”
“Paras Biopharmaceuticals has developed proprietary expression vectors based on the most optimum genetic codes selected for each amino acid of the therapeutic,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Genes are coupled with suitable Diabrid® partners to achieve a unique combination of therapeutic proteins and peptides.”
“The company not only possesses exceptional process development skills to achieve the highest levels of protein expression, but also has extensive experience in protein purification,” noted Chidambaram. “Its core strengths, ranging from media selection and development, optimization of process parameters, screening of resins to minimizing aggregation concepts in purification have earned the company a reputation for being an important innovator in biopharmaceuticals.”
About Paras Biopharmaceuticals
Paras Biopharmaceuticals Finland Oy is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides.
Paras’ work revolves around two main streams
About Frost & Sullivan
Frost & Sullivan is a Growth Partnership Company that works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. Its Growth Partnership supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure. For more than 50 years, Frost & Sullivan have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Paras Biopharmaceuticals Finland Oy
Oulu, Finland
Dr Mark Jackson – Research Associate and Company Administration
Kiviharjunlenkki 2, Oulu, FI-90220, Finland
Phone: +358 442905993
E-Mail: mark.jackson@parasbiopharma.com
Website: www.parasbiopharma.com
Paras Biopharmaceuticals acquires new Aglient Q-TOF to expand analytical capabilities
12th January 2016: Paras Biopharmaceuticals has announced the expansion of its analytical capabilities with the procurement of a Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) and UHPLC systems for peptide identification. This devices provides exceptional MS and MS/MS performance without compromises and will allow Paras to add to its existing analytical suite.
Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
Based on their products and its continuous drive to push the limits of Quality with innovations, Paras Biopharmaceuticals has received the ESQR's Quality Choice Prize 2016 for their hard work and achievements, in the presence of the international business community for its commitment to quality, excellence and continuous improvement. 12th December 2016 in Berlin, Germany
Biochemistry Students participate in fact-finding tour of our facility
As part of Paras Biopharmaceuticals' corporate social responsibility initiative to encourage students into the fields of biochemistry and biopharmaceutical production, on 18th November 2016 Paras Biopharmaceuticals welcomed Histoni Ry and its members to its Oulu-based facility. Histoni Ry is the student organisation of the biochemistry department at the University of Oulu.
Paras Biopharmaceuticals upgrades its purification suite to expand existing capabilities.
19th September 2016. Paras Biopharmaceuticals expands its purification suite with the addition of low-pressure AxiChrom columns from GE Healthcare Life Sciences. The most notable addition is the AxiChrom 300 column and AxiChrom Packing Master.
Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.
25th August 2016, - Oulu-based Paras Biopharmaceuticals Finland Oy has developed technology for the production of an osteoporosis drug (Recombinant Teriparatide) which will result into a very economical production of the medicine. International pharma companies are actively in discussions with Paras Biopharmaceuticals to further take regulatory work and bring the medicine to market.
Paras forms partnership with Novozymes (Denmark)
In collaboration with Novozymes (Denmark), Paras Biopharmaceuticals (Finland) announced that the partnership will use the successful VELTIS® technology to develop an improved version of a leading osteoporosis treatment. 24th November 2015
Paras' corporate social responsibility initiative
Biotechnology students from the University of Oulu take up the chance to explore Paras' facilities. 12th November 2015
Paras wins international award
On 11th December 2014 in Frankfurt, Germany, senior members of the Paras Team received an international award by the US company Frost & Sullivan.
Paras in the news: "Oulu doesn't give up"
Reported on 7th Aug 2014 by Helsinki-based business newspaper "Kauppalehti"
Paras' corporate social responsibility initiative
8th grade students from Oulu International School take up the chance to explore Paras' facilities. 22th April 2014
Paras' corporate social responsibility initiative
Biotechnology students from Tampere University of Technology take up the chance to explore Paras' facilities. 28th March 2014
Paras in the news: "Medicine cost down using Oulu-based knowledge"
Reported by Oulu's local newspaper "Kaleva" (13th October 2013)
Dr. Mark Jackson
Public Affairs
mark.jackson@parasbiopharma.com
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.
